Sort   by:  
 Page size 
UnknownEnoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Not available
S-EPMC9657896 | biostudies-literature
UnknownChemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.
Not available
S-EPMC5935540 | biostudies-literature
UnknownCombining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Not available
S-EPMC12648624 | biostudies-literature
UnknownShort-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Not available
S-EPMC6311344 | biostudies-literature
UnknownMycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Not available
S-EPMC5014629 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592 | biostudies-literature
UnknownCOVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Not available
S-EPMC7993930 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594 | biostudies-literature
UnknownNeutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Not available
S-EPMC11797383 | biostudies-literature
UnknownGlobal Retinoblastoma Presentation and Analysis by National Income Level.
Not available
S-EPMC7047856 | biostudies-literature
Sort   by:  
 Page size